Skip to content

Bicara Therapeutics BCAX Return on assets

Return on assets at other companies

Eli Lilly logo
Eli LillyLLY
24.5%+10.1pp
Amgen logo
AmgenAMGN
8.6%+2.1pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-51.4%+5.5pp
Immunome logo
ImmunomeIMNM
-46.7%-9.2pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-34.3%+2.7pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-43.7%-7.9pp

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's return on assets?
Bicara Therapeutics (BCAX) reported return on assets of -30.5% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.